Vernalis Plc is a research and development stage pharmaceutical company. The company provides pharmaceutical products for a range of medical disorders. It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development. The group has one marketed product, frovatriptan, for the acute treatment of migraines, an exclusive licensing agreement to develop and commercialize multiple novel products focused on the U.S. prescription cough and cold market as well as eight programmes in its NCE development pipeline. It has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with other pharmaceutical companies. The group product pipeline for central nervous system diseases include V158866 for the treatment of a range of pain disorders, which is in Phase I trial and V81444, an A2A receptor antagonists for the treatment for Parkinson's disease, which is in pre-clinical stage development. The company was founded by Keith G. McCullagh in 1986 and is headquartered in Wokingham, the United Kingdom.
100 Berkshire Place Wharfedale Road
Winnersh, BR RG41 5RD
SIC Code: 2834